
Natasha Hunter, MD
Advertisement
Articles by Natasha Hunter, MD


24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han

The Changing Landscape of Targeted Breast Cancer Therapies
Published: | Updated:
Experts provide perspective on the rapidly changing landscape of targeted therapies in breast cancer treatment, and the importance of matching the right agent with the right patient.
Advertisement
Latest Updated Articles
The Changing Landscape of Targeted Breast Cancer TherapiesPublished: April 10th 2020 | Updated: November 11th 2020
Advertisement
Advertisement
Trending on CancerNetwork
1
Will The FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma?
2
FDA Grants Tentative Approval to PNT2003 for GEP-NETs
3
FDA Grants Pre-Market Approval to AI Device for Breast Cancer Surgery
4
The Evolving Landscape of Immunotherapy in Breast Cancer
5

